A Leader in the Development of Inhaled Medicines

At iPharma, our goal is to become the world’s leading inhalation development contract research organization.

June 16, 2022
 — Kindeva Drug Delivery completed the acquisition of iPharma Labs, Inc. This acquisition combines iPharma’s deep expertise and track record in inhalation formulation and development of liquid, dry powder, and propellant-based therapies with Kindeva’s global expertise in developing, commercializing, and manufacturing inhaled therapies.

The entire team at iPharma has joined Kindeva and will continue to operate from their existing location.